Navigating the Antithrombotic Maze: What to do for Your ACS Patients in the Era of Contemporary PCI
Published: 01 September 2020
-
Views:
56
-
Likes:
7
-
Views:
56
-
Likes:
7
-
12m 18s
-
13m 38sPart 5 Q&As
-
2m 4sPart 1 Welcome Kurt Huber
-
15m 14sPart 2 Pre-treatment in NSTE-ACS – Dead or Alive? Davide Capodanno
Overview
In this series of videos Kurt Huber, Davide Capodanno, Stefan James and Roxana Mehran discuss Navigating the Antithrombotic Maze: What to do for Your ACS Patients in the Era of Contemporary PCI
Supported by an unrestricted educational grant from AstraZeneca
Learning Objectives
- Review the clinical landscape for antiplatelet therapy in patients with ACS.
- Discuss recent data on DAPT for patients with ACS
- Provide expert insight on application in routine clinical practice
More from this programme
Part 2
Pre-treatment in NSTE-ACS – Dead or Alive?
Part 3
Choice of Antithrombotic Agent in ACS: REACT-ing to Recent Trials
Part 4
When to leave Aspirin behind?
| 1 session | |
| When to leave Aspirin behind? | Watch now |
Faculty Biographies
Stefan James
Dr Stefan James is Professor of Cardiology at Uppsala University and Scientific Director of Uppsala Clinical Research Center. He is a Senior Interventional Cardiologist at Uppsala University Hospital Sweden. He graduated from Uppsala University Medical School and completed specialist training in Uppsala. He has previously held positions at the Karolinska Hospital, the University Hospital Örebro and Duke Clinical Research Institute, Duke University.